1. Hyperpigmentation of the gingival and buccal mucosa (and skin creases).
2. Primary adrenal insufficiency (Addison disease): Cortisol deficiency removes negative feedback on the pituitary-hypothalamic axis, leading to increased ACTH and $\alpha$-MSH production from the common precursor pro-opiomelanocortin (POMC).
3. Meningococcemia (Neisseria meningitidis) causing acute bilateral adrenal hemorrhage; known as Waterhouse-Friderichsen syndrome.
4. Electrolyte abnormalities:
   • Hyponatremia
   • Hyperkalemia
   • Hypoglycemia
   • Metabolic acidosis (normal anion gap)
   • Prerenal azotemia / elevated BUN
5. Standard high-dose ACTH (Synacthen/Cosyntropin) stimulation test (measuring baseline and 30/60-minute serum cortisol levels).

1. Increase the morning regular insulin dose by 1–2 units (and adjust overall daily insulin dose by 10–20% based on pre- and post-prandial glucose logs).
2. Over the preceding 3 months (8–12 weeks).
3. Retinopathy screening initiation:
   • After 5 years of diabetes duration in prepubertal children, OR
   • Starting at age 10–11 years / onset of puberty (whichever is earlier), then annually.
4. Preferred screening method: Dilated pupillary digital fundal photography (or dilated indirect ophthalmoscopy by an ophthalmologist).

Reference: Screening guidelines in pediatric diabetes:

• Retinopathy: After 5 years duration (or from puberty), annually by fundal photography.
• Nephropathy: After 5 years duration (or from puberty), annually by spot urine albumin-to-creatinine ratio (ACR).
• Thyroid disease: At diagnosis, then every 1–2 years (TSH, anti-TPO).
• Celiac disease: At diagnosis, then every 2–5 years (anti-tTG IgA).

1. Glycated hemoglobin reflects mean ambient glycemic control over the preceding 2–3 months (erythrocyte lifespan ~120 days).
2. Normal non-diabetic range: $4.0–5.6\mathrm{\%}$ ($<5.7\mathrm{\%}$).
3. Target ${\text{HbA}}_{1\text{c}}$ in pediatric Type 1 Diabetes (ISPAD / ADA guidelines):
   • $<7.0\mathrm{\%}$ ($<53\text{ mmol/mol}$) for most children if achievable without significant hypoglycemia.
   • $<7.5\mathrm{\%}$ where continuous glucose monitoring / advanced technology is unavailable.

1. Hyperthyroidism / Thyrotoxicosis.
2. Graves' disease (autoimmune stimulation of TSH receptors by TRAb / TSI).
3. Medical management:
   • Antithyroid drugs (Thionamides): Methimazole / Carbimazole ($0.5–1.0\text{ mg/kg/day}$ in 1–2 divided doses). (Propylthiouracil is avoided in children due to severe hepatotoxicity risk).
   • $\beta$-blockers: Propranolol ($1–2\text{ mg/kg/day}$ in 3 divided doses) for symptomatic control of adrenergic symptoms (tachycardia, tremors).
   • Definitive therapy if refractory: Radioactive iodine (${}^{131}\text{I}$) ablation or near-total thyroidectomy.

1. $\text{BMI}=\frac{\text{Weight in kg}}{(\text{Height in m}{)}^2}=\frac{38}{(1.22{)}^2}=\frac{38}{1.4884}\approx 25.5{\text{ kg/m}}^2$ (well above the 95th percentile for age and sex, indicating obesity).
2. Acanthosis nigricans, which denotes severe insulin resistance / hyperinsulinemia. Investigations: Fasting lipid profile, Oral Glucose Tolerance Test (OGTT) / fasting plasma glucose, and fasting serum insulin ($\text{HOMA-IR}$).
3. Musculoskeletal complications of childhood obesity:
   • Slipped Capital Femoral Epiphysis (SCFE)
   • Blount disease (Tibia vara)
   • Genu valgum ("knock knees")
   • Pes planus (flat feet)

1. Pheochromocytoma (chromaffin tissue catecholamine-secreting tumor).
2. Diagnostic confirmation:
   • 24-hour urinary fractionated metanephrines and normetanephrines (or plasma free metanephrines).
   • 24-hour urinary vanillylmandelic acid (VMA).
   • Contrast CT / MRI abdomen (adrenal protocol) and ${}^{123}\text{I}$-MIBG scintigraphy or ${}^{68}\text{Ga}$-DOTATATE PET-CT.
3. Preoperative medical management:
   • $\alpha$-adrenergic blockade first: Phenoxybenzamine ($0.5–1\text{ mg/kg/day}$ titrated) or Prazosin for 10–14 days to control BP and expand intravascular volume.
   • $\beta$-adrenergic blockade second: Propranolol or Atenolol started only AFTER adequate $\alpha$-blockade (to avoid unopposed $\alpha$-vasoconstriction and hypertensive crisis).

1. Turner syndrome (45,X / Gonadal dysgenesis).
2. Cardiovascular abnormalities:
   • Present finding: Coarctation of the Aorta (causing upper extremity hypertension and absent/delayed lower limb femoral pulses).
   • Other CVS anomalies: Bicuspid aortic valve (most common), aortic root dilatation / dissection, partial anomalous pulmonary venous connection (PAPVC).
3. Associated endocrine disorders:
   • Hypergonadotropic hypogonadism (streak gonads / ovarian failure)
   • Autoimmune thyroiditis (Hashimoto thyroiditis / hypothyroidism)
   • Type 2 diabetes / Impaired glucose tolerance with insulin resistance
4. Pubertal induction therapy:
   • Low-dose oral or transdermal Estrogen (e.g., $17\beta$-estradiol) initiated around 11–12 years of age, gradually titrated over 2–3 years.
   • Cyclic Progesterone added after 2 years of estrogen therapy or when breakthrough bleeding occurs to achieve regular menstrual withdrawal bleeding and protect endometrium.

1. McCune-Albright Syndrome (MAS) (due to postzygotic somatic activating mutation in GNAS gene).
2. Classic triad:
   • Peripheral (GnRH-independent) precocious puberty (recurrent autonomous ovarian follicular cysts)
   • Polyostotic fibrous dysplasia of bones
   • Large, irregular café-au-lait skin macules with "coast of Maine" jagged borders
3. Other hyperfunctioning endocrinopathies:
   • Hyperthyroidism (toxic nodular goiter)
   • GH excess / Gigantism / Acromegaly
   • Cushing syndrome (autonomous bilateral adrenal hyperplasia)
   • Renal phosphate wasting / hypophosphatemic rickets (FGF-23 excess)
4. Treatment:
   • Aromatase inhibitors (e.g., Letrozole or Anastrozole) to block estrogen synthesis
   • Estrogen receptor antagonists (e.g., Tamoxifen or Fulvestrant)
   • Bisphosphonates (Pamidronate/Zoledronic acid) for painful polyostotic fibrous dysplasia.

1. Definitions:
   • Somogyi Phenomenon (Rebound Hyperglycemia): Nocturnal hypoglycemia (around 2–3 AM) triggers a surge of counter-regulatory hormones (epinephrine, glucagon, cortisol, GH) producing early-morning rebound hyperglycemia.
   • Dawn Phenomenon: Early-morning (4–8 AM) hyperglycemia without preceding nocturnal hypoglycemia, caused by circadian physiological rise in Growth Hormone and cortisol together with declining nighttime insulin levels.
2. Differentiation:
   • Check blood glucose at 2:00 AM – 3:00 AM:
     • If 3:00 AM glucose is low (< 60–70 mg/dL) $\to$ Somogyi phenomenon.
     • If 3:00 AM glucose is normal or elevated (> 80–100 mg/dL) $\to$ Dawn phenomenon.
3. Treatment:
   • For Somogyi phenomenon: Decrease the evening intermediate/long-acting (NPH) insulin dose by 10–15% or provide a bedtime complex carbohydrate snack.
   • For Dawn phenomenon: Increase the evening/nighttime insulin dose by 10–15% or shift the evening NPH injection from dinnertime to bedtime (around 10:00 PM).

1. Congenital Adrenal Hyperplasia (CAH) due to 21-Hydroxylase deficiency (Salt-wasting classic form, 46,XX virilized female).
2. Autosomal recessive (CYP21A2 gene mutation on chr 6p21.3).
3. Prenatal diagnosis: Chorionic Villus Sampling (CVS) at 10–12 weeks or Amniocentesis at 15–18 weeks for CYP21A2 molecular genetic analysis (MLPA/Sanger sequencing).
4. Management in next pregnancy:
   • Start maternal oral Dexamethasone ($20\text{ µg/kg/day}$ in 3 divided doses, max 1.5 mg/day) as soon as pregnancy is confirmed (before 6–7 weeks) to suppress fetal pituitary ACTH and prevent virilization of female genitalia.
   • Perform CVS for fetal sex determination and CYP21A2 mutation: If fetus is male or an unaffected female, stop dexamethasone; if affected 46,XX female, continue dexamethasone until term.
5. Treatment:
   • Glucocorticoid replacement: Oral Hydrocortisone ($10–15{\text{ mg/m}}^2/\text{day}$ in 3 divided doses; doubled/tripled during stress/illness).
   • Mineralocorticoid replacement: Oral Fludrocortisone ($0.05–0.2\text{ mg/day}$).
   • Sodium chloride supplementation: $1–3\text{ g/day}$ (17–51 mEq/day) in infants.
   • Surgical feminizing genitoplasty (clitoroplasty/vaginoplasty) at 6–12 months of age.

1. Primary Hypoparathyroidism (or Pseudohypoparathyroidism).
2. Serum intact PTH is low / undetectable in primary hypoparathyroidism (elevated in pseudohypoparathyroidism); $1,25(\text{OH}{)}_2{\text{D}}_3$ (Calcitriol) is low in both.
3. Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED / Autoimmune Polyglandular Syndrome Type 1 [APS-1], due to AIRE gene mutation).
4. Bilateral symmetrical basal ganglia calcifications (and subcortical white matter calcifications).

1. Lab findings in SIADH:
   • a. False (Urine Osmolality is inappropriately concentrated, typically $>100–300\text{ mOsm/kg}$).
   • b. True (Euvolemic / mildly increased plasma volume without clinical edema).
   • c. True (Urine $\text{Na}>20–40\text{ mEq/L}$ despite hyponatremia due to natriuresis).
   • d. False (Serum uric acid and BUN are low due to dilution and increased urate clearance).
2. Drugs increasing ADH: Carbamazepine, Vincristine, Cyclophosphamide, Tricyclic antidepressants (TCAs), SSRIs.
3. Fluid restriction: Restrict total fluid intake to $50–70\mathrm{\%}$ of maintenance ($600–1000{\text{ mL/m}}^2/\text{day}$).
4. Pharmacotherapy: Demeclocycline (causes nephrogenic DI), Tolvaptan / Conivaptan (vasopressin V2 receptor antagonists), or oral urea / salt tablets.
5. Respiratory illnesses: Acute bronchiolitis (RSV), bacterial pneumonia, tuberculosis, status asthmaticus.
6. Phenytoin (inhibits ADH release).

1. Isolated unilateral or bilateral breast development in young girls without other signs of sexual maturation (no pubic/axillary hair, no growth spurt, no bone age advancement).
2. Benign variant when presenting before 2–3 years of age (often self-limiting with spontaneous regression).
3. Exaggerated / Atypical thelarche: Breast development accompanied by mild acceleration of bone age or fluctuating estradiol levels, requiring close surveillance for progression to central precocious puberty.
4. Hormone profile in benign premature thelarche:
   • Basal and GnRH-stimulated LH: Prepubertal / suppressed ($<0.3\text{ IU/L}$)
   • FSH: Normal to mildly elevated (FSH-predominant response to GnRH)
   • Serum Estradiol: Prepubertal / low ($<10–20\text{ pg/mL}$)
5. Pelvic USG findings: Prepubertal tubular uterus (length $<3.5\text{ cm}$, uterine volume $<1.5–2\text{ mL}$, endometrial stripe absent); normal small ovaries ($<1–2{\text{ cm}}^3$) with small non-dominant follicles ($<5\text{ mm}$).

1. Hyperthyroidism / Thyrotoxicosis.
2. Graves' disease (autoimmune stimulation by TSH-receptor antibodies [TRAb/TSI] leading to diffuse goiter and thyroid-associated orbitopathy/exophthalmos).
3. Other causes of thyrotoxicosis:
   • Toxic solitary adenoma
   • Toxic multinodular goiter (Plummer disease)
   • Subacute granulomatous thyroiditis (de Quervain thyroiditis)
   • Chronic autoimmune thyroiditis (Hashitoxicosis - early phase)
   • Exogenous thyroid hormone ingestion (factitious)
   • TSH-secreting pituitary adenoma
4. Investigations:
   • Free $T_3$, Free $T_4$ (both elevated), TSH (suppressed $<0.01\text{ µIU/mL}$)
   • Serum TSH receptor antibodies (TRAb / TSI) and anti-TPO antibodies
   • Technetium-99m (${}^{99m}\text{Tc}$) or ${}^{123}\text{I}$ thyroid scintigraphy (diffuse increased uptake)
   • Thyroid USG with color Doppler (increased vascular flow - "thyroid inferno").
5. Drug classes:
   • Antithyroid drugs (Thionamides): Methimazole or Carbimazole
   • $\beta$-blockers: Propranolol or Atenolol.

1. Tanner Stage B2 (Breast Stage 2 / Thelarche).
2. Tanner Stage G2 / P2 (Genital Stage 2, Pubic Hair Stage 2).
3. Sub-stages of adolescence:
   • Early adolescence: 10–13 years
   • Middle adolescence: 14–16 years
   • Late adolescence: 17–20 years

1. Cushing Syndrome (with virilization / adrenal tumor).
2. Autonomous adrenal neoplasm (Adrenocortical Adenoma or Adrenocortical Carcinoma). (In children $<7$ years, adrenal tumors are the commonest cause of endogenous Cushing syndrome; in children $>7$ years, ACTH-secreting pituitary adenoma [Cushing disease] predominates).
3. First-line screening tests:
   • 24-hour urinary free cortisol (UFC) excretion (at least 2 collections)
   • Overnight low-dose Dexamethasone Suppression Test (1 mg DST or $30\text{ µg/kg}$ DST)
   • Late-night salivary cortisol (at 11:00 PM)
   • Loss of normal diurnal plasma cortisol rhythm
4. Adrenolytic / steroidogenesis-inhibiting drugs:
   • Ketoconazole (inhibits CYP17 and 11$\beta$-hydroxylase)
   • Metyrapone (inhibits 11$\beta$-hydroxylase)
   • Mitotane (adrenolytic agent)
   • Aminoglutethimide / Etomidate

1. Differential diagnosis of short 4th metacarpal:
   • Pseudohypoparathyroidism (Albright Hereditary Osteodystrophy)
   • Pseudo-pseudohypoparathyroidism (PPHP)
   • Turner syndrome (45,X)
   • Klinefelter syndrome (47,XXY)
   • Ellis-van Creveld syndrome
   • Idiopathic / hereditary brachydactyly
2. Syndromes with Radial Ray Defects:
   • Fanconi Anemia (FA)
   • Thrombocytopenia-Absent Radius (TAR) syndrome
   • Holt-Oram syndrome (cardiac defects + radial ray)
   • VACTERL association
   • Baller-Gerold syndrome
   • Diamond-Blackfan anemia
3. Fibrodysplasia Ossificans Progressiva (FOP / Myositis ossificans progressiva) characterized by congenital hallux valgus (microdactyly of great toes) and progressive heterotopic extraskeletal endochondral ossification.

1. Pseudohypoparathyroidism Type 1a (PHP-1a / Albright Hereditary Osteodystrophy [AHO]).
2. Ellsworth-Howard test (PTH infusion test): Blunted or absent increase in urinary cyclic AMP (cAMP) and urinary phosphate excretion (confirming end-organ PTH receptor resistance).
3. Autosomal dominant with genomic imprinting (maternally inherited inactivating mutation of the GNAS gene encoding the $G{\alpha }_s$ protein subunit).
4. Tuberous sclerosis (Autosomal dominant).

1. Dried blood spot 17-hydroxyprogesterone (17-OHP) assay by immunoassay / tandem mass spectrometry (LC-MS/MS).
2. Definition: Stretched penile length (SPL) $<-2.5\text{ SD}$ below the mean for age ($<1.9–2.0\text{ cm}$ in a full-term neonate; normal term mean SPL $\approx 3.5\pm 0.4\text{ cm}$).
3. Causes / syndromes:
   • Hypogonadotropic hypogonadism: Kallmann syndrome, Prader-Willi syndrome, CHARGE syndrome, congenital hypopituitarism (GH/LH/FSH deficiency)
   • Hypergonadotropic hypogonadism: Klinefelter syndrome, testicular dysgenesis/anorchia
   • Robinow syndrome (fetal face syndrome)
   • Idiopathic micropenis
4. Paraphimosis: A urological emergency where a retracted, tight foreskin becomes trapped behind the coronal sulcus, leading to venous and lymphatic congestion, glans edema, and arterial compromise.
5. Management:
   • Manual reduction: Apply manual compression to reduce glans edema (with topical ice/osmotic agent like 50% dextrose), followed by gentle distal traction on the prepuce and pushing the glans proximally.
   • Puncture technique / dorsal slit of the constricting band under local anesthesia if manual reduction fails.
   • Elective circumcision after resolution of acute inflammation.

1. Central (GnRH-dependent) Precocious Puberty secondary to Hypothalamic Hamartoma (presenting with gelastic seizures and accelerated linear growth).
2. Diagnostic investigations:
   • High-resolution MRI Brain (with thin cuts through the hypothalamus and pituitary to identify sessile or pedunculated tuber cinereum hamartoma)
   • Video-EEG (to capture gelastic seizures)
   • Baseline and GnRH agonist stimulation test (showing pubertal LH surge $>5\text{ IU/L}$)
   • Serum estradiol and pelvic USG (uterine and ovarian enlargement)
   • Bone age radiograph (advanced bone age).
3. Medical treatment:
   • Long-acting GnRH agonists (e.g., Leuprolide acetate depot $0.2–0.3\text{ mg/kg}$ every 4–12 weeks, or Triptorelin) to desensitize pituitary GnRH receptors and arrest pubertal progression.
   • Antiseizure medications (e.g., Carbamazepine, Lamotrigine, Levetiracetam) for seizures.
4. Refractory cases: Stereotactic radiofrequency ablation, Gamma Knife radiosurgery, MRI-guided laser interstitial thermal therapy (LITT), or endoscopic transsphenoidal/microsurgical resection.

Table A Answers:

1. Primary Hypothyroidism (Hashimoto / Thyroid dysgenesis).
2. Secondary (Central / Pituitary) Hypothyroidism.
3. Thyroxine-Binding Globulin (TBG) deficiency (Total $T_4$ is low, but Free $T_4$ and TSH are normal).
4. Subclinical / Compensated Hypothyroidism.

Table B Answers:

• 1 $\to$ Generalized aminoaciduria (Renal Fanconi syndrome in Cystinosis).
• 3 $\to$ Markedly Decreased Serum Alkaline Phosphatase (hallmark of Hypophosphatasia due to ALPL gene mutation).
• 4 $\to$ Markedly Increased $1,25(\text{OH}{)}_2{\text{D}}_3$ (due to vitamin D receptor [VDR] mutation in VDDR Type II).
• 5 $\to$ Markedly Decreased $1,25(\text{OH}{)}_2{\text{D}}_3$ (due to $CYP27B1$ $1\alpha$-hydroxylase deficiency in VDDR Type I).

• Patient A: Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) (Euvolemic hyponatremia with inappropriately high ADH).
• Patient B: Cerebral Salt Wasting (CSW) (Hypovolemic hyponatremia with massive natriuresis).
• Patient C: Central Diabetes Insipidus (CDI) (Hypernatremic polyuria with low/absent ADH).

1. Van Wyk-Grumbach Syndrome (severe primary juvenile hypothyroidism presenting with precocious thelarche, multicystic ovaries, uterine bleeding, and delayed bone age). Underlying mechanism: Cross-reactivity of extremely high TSH at ovarian FSH receptors (and hyperprolactinemia due to high TRH).
2. Investigations:
   • Free $T_4$ (markedly low), Free $T_3$, anti-TPO and anti-thyroglobulin antibodies
   • Serum Prolactin (elevated)
   • Pelvic USG (shows bilateral multicystic enlarged ovaries and enlarged uterus)
   • MRI Brain / Pituitary (shows pituitary hyperplasia/macroadenoma reversible with $T_4$).
3. Causes of secondary central activation after peripheral precocious puberty:
   • Congenital Adrenal Hyperplasia (after initiating glucocorticoid therapy)
   • McCune-Albright syndrome
   • Familial male-limited precocious puberty (testotoxicosis).
4. Clinical definitions:
   • Girls: Onset of secondary sexual characteristics (breast budding) before 8 years of age (or menarche before 9 years).
   • Boys: Testicular enlargement ($\ge 4\text{ mL}$ volume or length $\ge 2.5\text{ cm}$) before 9 years of age.
5. Treatment: Levothyroxine replacement therapy ($L\text{-thyroxine }100{\text{ µg/m}}^2/\text{day}$ or $2–3\text{ µg/kg/day}$); causes prompt regression of breast enlargement, resolution of ovarian cysts, normalization of pituitary size, and resumption of linear growth.

1. Acquired Hypothyroidism; most common cause is Hashimoto thyroiditis (Chronic Autoimmune Lymphocytic Thyroiditis).
2. Investigations:
   • Serum Free $T_4$ (low) and TSH (elevated)
   • Anti-Thyroid Peroxidase (anti-TPO) and Anti-Thyroglobulin (anti-Tg) antibodies
   • Thyroid USG (heterogeneous, hypoechoic parenchyma with micronodularity)
   • Bone age radiograph (epiphyseal dysgenesis, marked delay in skeletal maturation).
3. School performance: Academic performance is surprisingly well-preserved in acquired juvenile hypothyroidism (unlike congenital hypothyroidism), though processing speed and alertness may be slowed.
4. Post-treatment behavioral changes: Restlessness, decreased attention span, hyperactive behavior, sleep difficulties, and transient decline in school grades as metabolic rate normalizes.
5. Long-term height effect: Although significant catch-up growth occurs, persistent untreated long-standing juvenile hypothyroidism may lead to a permanent deficit of $\sim 5–7\text{ cm}$ in final adult height.

1. Neonatal Graves' Disease / Congenital Thyrotoxicosis (due to transplacental transfer of maternal thyroid-stimulating immunoglobulin [TSI / TRAb]).
2. Diagnostic tests:
   • Serum Free $T_4$ and Free $T_3$ (markedly elevated), TSH (suppressed $<0.01\text{ µIU/mL}$).
   • Neonatal and maternal TSH-Receptor Antibodies (TRAb / TSI) $>300–500\mathrm{\%}$ of control.
3. Treatment:
   • Methimazole: $0.25–1.0\text{ mg/kg/day}$ orally in 2–3 divided doses (or Propylthiouracil $5–10\text{ mg/kg/day}$).
   • Propranolol: $2\text{ mg/kg/day}$ in 3 divided doses to control tachycardia and sympathetic hyperactivity.
   • Lugol's iodine (5% iodine + 10% KI): 1 drop orally TDS to acutely block thyroid hormone release (given 1 hour after antithyroid drug).
   • Prednisolone ($2\text{ mg/kg/day}$) in severe refractory cases.
     (Self-limiting disorder resolving in 2–4 months as maternal IgG antibodies are cleared from infant's circulation).

• Diagnosis A: Growth Hormone Deficiency / Hypopituitarism
• Diagnosis B: Hypothyroidism
• Diagnosis C: Constitutional Delay of Growth and Puberty (CDGP)
• Diagnosis D: Familial (Genetic) Short Stature (FSS)

1. Primary Hyperparathyroidism (solitary parathyroid adenoma or parathyroid hyperplasia).
2. Subperiosteal bone resorption (particularly at the radial margins of the middle phalanges, distal clavicles, and "salt-and-pepper" skull appearance / osteitis fibrosa cystica).
3. Familial Hypocalciuric Hypercalcemia (FHH / CASR mutation); ruled out by urinary calcium excretion (urinary calcium is low in FHH with Calcium-to-Creatinine clearance ratio $<0.01$, whereas urinary calcium is elevated in primary hyperparathyroidism with ratio $>0.02$).
4. Severe hypocalcemia ("Hungry Bone Syndrome" / acute transient hypoparathyroidism) leading to tetany and hypocalcemic seizures following surgical excision of the hyperactive parathyroid tissue.

1. Acanthosis Nigricans (Obesity-associated / Pseudoacanthosis nigricans). Other anatomical sites: Flexural creases, antecubital fossae, popliteal fossae, groin, knuckles, umbilicus, lips, and mucosal surfaces.
2. Severe hyperinsulinemia, peripheral insulin resistance, and increased risk for Metabolic Syndrome / Type 2 Diabetes Mellitus.
3. Clinical recommendations:
   • Comprehensive screening: Fasting lipid panel, fasting glucose and OGTT, liver transaminases (NAFLD screening), and blood pressure monitoring.
   • Structured weight management: Caloric restriction with whole foods, elimination of sugar-sweetened beverages.
   • Physical activity: At least 60 minutes of moderate-to-vigorous aerobic exercise daily with reduction of recreational screen time to $<2\text{ hours/day}$.
   • Family-centered lifestyle modifications.